Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : AMV564, a novel first-in-class agent that depletes MDSC and activates T cells, is being investigated in a Phase 1 clinical trial in advanced solid tumors. Phase 1 data support dose and schedule of AMV564 for expansion cohorts in selected solid tumor indi...
Product Name : AMV564
Product Type : Antibody
Upfront Cash : Inapplicable
September 11, 2020
Details : AMV564 translational data for MDSC depletion, Treg control, favorable effector CD8 and CD4 Th1 polarization, along with a cytokine and chemokine milieu conducive to T cell trafficking and antigen presentation is consistent with relief of immune suppressi...
Product Name : AMV564
Product Type : Antibody
Upfront Cash : Inapplicable
June 23, 2020
Lead Product(s) : AMV564,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AMV564 showed single-agent activity including one complete response in a heavily pre-treated, checkpoint inhibitor-refractory ovarian cancer patient for whom treatment is ongoing.
Product Name : AMV564
Product Type : Antibody
Upfront Cash : Inapplicable
May 29, 2020
Lead Product(s) : AMV564,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
